Drugs / GB2064
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04679870 | Jun 2021 → Dec 2023 overdue | myelofibrosis | Galecto Biotech AB | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB2064 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04679870 ↗ |
| Known as | PAT-1251 | “GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day” NCT04679870 ↗ |
| Action | Inhibit | “inhibitor of LOXL2” NCT04679870 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT04679870 ↗ |
| Route | Oral | “administered orally” NCT04679870 ↗ |
| Target | LOXL2 | “inhibitor of LOXL2” NCT04679870 ↗ |